<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C914A30D-72C0-427C-B532-D798A26A0710"><gtr:id>C914A30D-72C0-427C-B532-D798A26A0710</gtr:id><gtr:name>Marie Curie Cancer Care</gtr:name><gtr:department>Policy &amp; Stategy</gtr:department><gtr:address><gtr:line1>Marie Curie Cancer Care</gtr:line1><gtr:line2>89 Albert Embankment</gtr:line2><gtr:postCode>SE1 7TP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C914A30D-72C0-427C-B532-D798A26A0710"><gtr:id>C914A30D-72C0-427C-B532-D798A26A0710</gtr:id><gtr:name>Marie Curie Cancer Care</gtr:name><gtr:address><gtr:line1>Marie Curie Cancer Care</gtr:line1><gtr:line2>89 Albert Embankment</gtr:line2><gtr:postCode>SE1 7TP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5D46FAA2-A53B-4499-87D4-FDFE93ECB4DE"><gtr:id>5D46FAA2-A53B-4499-87D4-FDFE93ECB4DE</gtr:id><gtr:firstName>Jan</gtr:firstName><gtr:surname>Lowe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7C20FED8-AE1F-4177-B788-4E041DB88600"><gtr:id>7C20FED8-AE1F-4177-B788-4E041DB88600</gtr:id><gtr:firstName>Linda</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Amos</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1877F1E9-F7D5-4360-A4FF-5E9648E048E4"><gtr:id>1877F1E9-F7D5-4360-A4FF-5E9648E048E4</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Cross</gtr:surname><gtr:orcidId>0000-0002-0004-7832</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200542"><gtr:id>835E59FE-6558-4830-9DA9-173A8E35A611</gtr:id><gtr:title>High resolution structure-function of tubulin</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200542</gtr:grantReference><gtr:abstractText>We are trying to understand the detailed structural mechanism by which microtubules are built.

Microtubules are the railway system of the cell. A network of microtubules stretches through the cell, connecting important destinations. In much the same way that countries transport cargo along railway lines, so cells transport cargo along microtubules.

Not surprisingly, microtubules are crucial to the life of cells. In particular, they are needed for cell division, when a tremendous amount of re-organization takes place. 

The building block of microtubules is a protein called tubulin. Several important cancer treatments work by binding to tubulin and preventing the cell from re-organizing its microtubules. 

To improve existing cancer medicines, and to find new ones, we need to understand the programme of shape-changes that tubulin undergoes as it assembles into microtubules. We have found a way to obtain very pure tubulin from yeast. We are analysing its fine structure, and the way this structure changes as the tubulin building-blocks assemble themselves into microtubules.

Our project is an example of basic structural biology, applied to a problem of great medical importance.</gtr:abstractText><gtr:technicalSummary>The low resolution structure of axonemal microtubules was first described in groundbreaking electron microscope studies by Amos and Klug in 1974. The major insights in the intervening 28 years have come from the discovery of dynamic instability in 1984 by Mitchison and Kirschner, and from the 4? electron diffraction map of tubulin by Nogales et al in 1998. The Nogales map is a substantial achievement, but is nonetheless still at too low a resolution to address the major problem, that of understanding the structure, and the conformational changes available to it, at atomic resolution. Solving this problem would open the possibility of understanding microtubule dynamics and microtubule-dependent cell biological processes at the molecular level, reveal the mechanisms of therapeutically important microtubule-active drugs such as taxol, and reveal potential avenues to new drugs directed at microtubules and their partner proteins.

We propose a novel attack on the atomic structure of tubulin, using a recent technical development in the Cross lab at MCRI. Methods have recently been developed for the expression and isolation in milligram quantities of ultra pure, fully functional single isoform tubulin from S.pombe. We believe that this technical development, together with the ability readily to make site-directed tubulin mutants, affords a very much improved prospect of obtaining well-ordered crystals for x-ray diffraction, and of substantially increasing the resolution of cryoEM. We propose an extensive programme of structure-function studies on tubulin and site-directed tubulin mutants, combining crystallographic (Lowe) and cryoEM (Amos) studies at MRC-LMB, with in vitro and in vivo studies of microtubule dynamics (Cross) at MCRI. Preliminary work on a modest scale over the last two years has established the feasibility of this approach, and relevant data are reported below. We show that it is possible not only to produce pure single-isoform wild type tubulin, but also to design and test tubulin mutants in vivo, and to extract and purify the mutant protein for in vitro dynamics measurements and for structural studies. 

We believe we have here a window of opportunity to make rapid progress on this important problem, at the same time advancing a major strategic goal of the MRC, that of harnessing basic structural biology to the solution of important medical problems, including cancer. We request MRC strategic funding for five years to allow us to buy equipment for large-scale yeast culture, and for salaries for one postdoctoral recruit, one RA and one student.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>499007</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Syngenta</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>BBSRC Industrial Partnership Award with Syngenta</gtr:description><gtr:id>CA5F6C22-CE73-43F3-8F60-C1796ECCA888</gtr:id><gtr:impact>nothing yet</gtr:impact><gtr:outcomeId>DN5evWTaYKC-1</gtr:outcomeId><gtr:partnerContribution>Large scale protein production, expertise on chemical biology of tubulin and microtubules</gtr:partnerContribution><gtr:piContribution>Expertise in microtubule protein purification, as gained thanks to MRC Strategic Award funding</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cafe Scientifique</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>23174FBF-285D-497D-9DDC-B74934991E18</gtr:id><gtr:impact>Two way results - audience members have since been in touch for more details with an interest in working together, whilst I have attended other Cafe Scientifique talks as an audience member.

Considering starting a Warwick event.</gtr:impact><gtr:outcomeId>HzREffGsRY8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>open evenings / nurse / school / fundraiser visits - Marie Curie Institute</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>128DECC5-7C03-4996-9717-2683D2F9D3FA</gtr:id><gtr:impact>I have several times presented at open evening events in our Institute, speaking to the general public (= potential donors to cancer research), aiming to explain the role of basic research in general, and our research in particular, in improving future medicine. I have also spoken to Marie Curie nurses, along the same lines.

Donations. We also now have a scientific fundraiser entirely devoted to explaining the work of the Institute to potential donors.</gtr:impact><gtr:outcomeId>143F8040636</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>185772</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR Project Grant</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:fundingRef>09-0221</gtr:fundingRef><gtr:id>21E6807C-93D4-42F7-BD61-47650B321448</gtr:id><gtr:outcomeId>1C03506BEF10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>530000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC IPA</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>D11A3961-6080-4378-8D47-F4AB779BAADA</gtr:id><gtr:outcomeId>o7iVxc6Uc6R</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1221148</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Investigator Award</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>103895/Z/14/Z</gtr:fundingRef><gtr:id>5F77B58B-FBE4-4D6F-84FB-A7969298DE5E</gtr:id><gtr:outcomeId>545aa13a814218.17075641</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Cancer Care Programme Funding</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Marie Curie</gtr:fundingOrg><gtr:id>C77ADE38-2F7E-4544-A8AE-453F4B98386C</gtr:id><gtr:outcomeId>MRrqdmwNDcx0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Tubulin is the protein building block of microtubules. We developed a method for purifying large amounts of isotypically-pure tubulin from a widely-used disease model, the yeast Schizosacharomyces pombe.</gtr:description><gtr:id>B60BA39D-F27B-4861-B5F7-5FF3E3D45E20</gtr:id><gtr:impact>Following publication, we were approached by Syngenta, an agrochemical and seeds company, to develop a purification of tubulin from a disease-causing yeast, S. tritici. Syngenta need this protein in order to be able to test the safety of their anti-tubulin crop-protection agents. To pursue this, we obtained &amp;pound;0.5M BBSRC IPA funding in partnership with Syngenta. This 3 year award runs from Oct 2014-Oct 2017.</gtr:impact><gtr:outcomeId>BD737FBA1E4</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>S. pombe tubulin</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8A6C8D15-4EF7-4066-8C04-29270404D951</gtr:id><gtr:title>Review: Mechanochemistry of the kinesin-1 ATPase.</gtr:title><gtr:parentPublicationTitle>Biopolymers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3ffb9eda85a188b87d89d9d0cb2d46a"><gtr:id>b3ffb9eda85a188b87d89d9d0cb2d46a</gtr:id><gtr:otherNames>Cross RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3525</gtr:issn><gtr:outcomeId>5aa9638051c6c0.38723128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>948A9E44-B1DC-42FE-AD98-C1D7BBEF99DD</gtr:id><gtr:title>An ATP gate controls tubulin binding by the tethered head of kinesin-1.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3009b4f91d9299544c46a9ad09941624"><gtr:id>3009b4f91d9299544c46a9ad09941624</gtr:id><gtr:otherNames>Alonso MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>58C883432FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CDFBBC4-9066-497C-85B8-72CC1B8EA286</gtr:id><gtr:title>S. pombe kinesins-8 promote both nucleation and catastrophe of microtubules.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc17c5c2de96fb21f0dd48ba069d4f3a"><gtr:id>fc17c5c2de96fb21f0dd48ba069d4f3a</gtr:id><gtr:otherNames>Erent M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15797_27_22363481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8ACEF28-6F45-42A7-8B4A-1B3700F2C458</gtr:id><gtr:title>Alp7/TACC-Alp14/TOG generates long-lived, fast-growing MTs by an unconventional mechanism.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c8da2e7d45ef858592648ed497d5b4d"><gtr:id>3c8da2e7d45ef858592648ed497d5b4d</gtr:id><gtr:otherNames>Hussmann F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56e03df1c659f9.84176433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AFCE718-6EF2-4C05-98EF-096A37BFECDE</gtr:id><gtr:title>Mal3 masks catastrophe events in Schizosaccharomyces pombe microtubules by inhibiting shrinkage and promoting rescue.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0de50929e0fa49abbe0d8df5d045dccc"><gtr:id>0de50929e0fa49abbe0d8df5d045dccc</gtr:id><gtr:otherNames>Katsuki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>7671A15D005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C787D1B5-A203-4335-9464-720F511640CE</gtr:id><gtr:title>Mal3, the Schizosaccharomyces pombe homolog of EB1, changes the microtubule lattice.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b4edfe1ad97a1cc71946b504d9eae4f"><gtr:id>2b4edfe1ad97a1cc71946b504d9eae4f</gtr:id><gtr:otherNames>des Georges A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>951C3101A14</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7F44C40-B15A-4D37-B159-5C9600D598B2</gtr:id><gtr:title>Preparation of dual-color polarity-marked fluorescent microtubule seeds.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0de50929e0fa49abbe0d8df5d045dccc"><gtr:id>0de50929e0fa49abbe0d8df5d045dccc</gtr:id><gtr:otherNames>Katsuki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>978-1-61779-251-9</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56df560cadb5a5.71378811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1C00905-C8CD-4670-8977-320E579B66C1</gtr:id><gtr:title>Ectopic A-lattice seams destabilize microtubules.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0de50929e0fa49abbe0d8df5d045dccc"><gtr:id>0de50929e0fa49abbe0d8df5d045dccc</gtr:id><gtr:otherNames>Katsuki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>545a9d3e55e161.33972352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D4D66F0-E877-4F47-9AB3-FE23AB2DDCF6</gtr:id><gtr:title>Purification of tubulin from the fission yeast Schizosaccharomyces pombe.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2b1e3e3141cfc97e3d4539323eb053a"><gtr:id>f2b1e3e3141cfc97e3d4539323eb053a</gtr:id><gtr:otherNames>Drummond DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>A2ZhcbSnf4L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A57118A4-0BCA-423E-9AE9-F9CDF6FF60E7</gtr:id><gtr:title>Nucleotide- and Mal3-dependent changes in fission yeast microtubules suggest a structural plasticity view of dynamics.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7def6d1bb4163e2ca21ad7886e949664"><gtr:id>7def6d1bb4163e2ca21ad7886e949664</gtr:id><gtr:otherNames>von Loeffelholz O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa96380a14e39.37126471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A45A234-BA6E-4A5B-9ED0-7811E951A241</gtr:id><gtr:title>Schizosaccharomyces pombe kinesin-5 switches direction using a steric blocking mechanism.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e37d8bea5b37f5b5304325237b365326"><gtr:id>e37d8bea5b37f5b5304325237b365326</gtr:id><gtr:otherNames>Britto M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5aa96380c8bce4.69881566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B983DC59-C967-470A-A258-25AE3CC7A3E6</gtr:id><gtr:title>The kinesin-14 Klp2 organizes microtubules into parallel bundles by an ATP-dependent sorting mechanism.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf113a1f04e52ec61e80686b4cf62604"><gtr:id>cf113a1f04e52ec61e80686b4cf62604</gtr:id><gtr:otherNames>Braun M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>157130D6732</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200542</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>